DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis

Company Overview

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Key Stats

• Today's Range: $4.00 to $4.23
• 50-Day Range: $3.38 to $5.24
• 52-Week Range: $2.14 to $6.82
• Volume: 80,803 shs
• Average Volume: 80,919 shs
• Market Capitalization: $174.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

DiaMedica Therapeutics Stock Analysis - MarketRank™

DiaMedica Therapeutics scored higher than 29% of companies evaluated by MarketBeat, and ranked 776th out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

DiaMedica Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

DiaMedica Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for DiaMedica Therapeutics are expected to decrease in the coming year, from ($0.59) to ($0.80) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DiaMedica Therapeutics is -7.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of DiaMedica Therapeutics is -7.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

DiaMedica Therapeutics has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.45% of the outstanding shares of DiaMedica Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

DiaMedica Therapeutics has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in DiaMedica Therapeutics has recently increased by 66.86%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DiaMedica Therapeutics does not currently pay a dividend.

Dividend Growth

DiaMedica Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.45% of the outstanding shares of DiaMedica Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

DiaMedica Therapeutics has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in DiaMedica Therapeutics has recently increased by 66.86%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.74

News Sentiment

DiaMedica Therapeutics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for DiaMedica Therapeutics this week, compared to 1 article on an average week.

MarketBeat Follows

3 people have added DiaMedica Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, DiaMedica Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.30% of the stock of DiaMedica Therapeutics is held by insiders.

Percentage Held by Institutions

Only 10.12% of the stock of DiaMedica Therapeutics is held by institutions.

DMAC Stock Analysis - Frequently Asked Questions

How have DMAC shares performed this year?

DiaMedica Therapeutics' stock was trading at $5.43 on January 1st, 2025. Since then, DMAC stock has decreased by 25.2% and is now trading at $4.06.
View the best growth stocks for 2025 here.

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) released its earnings results on Tuesday, May, 13th. The company reported ($0.18) earnings per share for the quarter, meeting the consensus estimate of ($0.18).
Read the conference call transcript.

When did DiaMedica Therapeutics IPO?

DiaMedica Therapeutics (DMAC) raised $18 million in an initial public offering on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

Who are DiaMedica Therapeutics' major shareholders?

DiaMedica Therapeutics' top institutional shareholders include First Manhattan CO. LLC. (1.42%), Royal Bank of Canada (0.36%), Goldman Sachs Group Inc. (0.28%) and Jane Street Group LLC (0.23%). Insiders that own company stock include Koch Thomas Von, David J Wambeke, Randall Michael Giuffre, Dietrich John Pauls and Scott Kellen.
View institutional ownership trends.

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DiaMedica Therapeutics investors own include NVIDIA (NVDA), ADMA Biologics (ADMA), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX), Ardelyx (ARDX) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 5/24/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DMAC
• CIK: 1401040
• Web: www.diamedica.com
• Phone: (763) 496-5454
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +97.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-19,380,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -43.67%
• Return on Assets: -40.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.81
• Quick Ratio: 11.81

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.35 per share
• Price / Book: 3.01

Miscellaneous

• Outstanding Shares: 42,883,000
• Free Float: 39,682,000
• Market Cap: $174.10 million
• Optionable: Optionable
• Beta: 1.29